European Society of Cardiology 2015 Congress
Billed as â€œThe world's largest and most influential cardiovascular event,â€ the European Society of Cardiology 2015 Congress will feature 5 days of scientific sessions covering more than 150 topics in cardiovascular medicine.
Q&A With Cecilia Linde From Karolinska University: Physical Activity in the Fight Against Obesity and Debating Diagnosis Methods for CRT
Q&A With W. Frank Peacock IV From Baylor College of Medicine: Taking a Closer Look at Benefits and Risks of Rivaroxaban
Q&A With Jack Reich From Renova Therapeutics: Gene Therapy for Congestive Heart Failure Shows Promise in Early Trials
Q&A With Athena Poppas From Brown University: New Innovations in Cardiovascular Imaging Show Clearer Picture for Doctors
Q&A With Michael Farkouh From the University of Toronto: Monitoring Blood Pressure and Stroke Risk in Bypass Patients
Q&A With Dirk Westermann From University Medical Center Hamburg: New Test Could Provide Fast Myocardial Infarction Diagnosis in Emergency Rooms
When a patient checks into the emergency room, whether on their own or in an ambulance, time is of the essence to make the correct diagnosis. As technology improves so does the ability to make diagnoses in medicine that much faster. This way doctors can treat the patients that need the help the most while the others can be safely discharged and sent home.
Q&A With Dipak Kotecha From the University of Birmingham: 'Mega Trial' Looks at Results of Heart Failure Results For Age and Gender
Q&A With Dipak Kotecha From the University of Birmingham: Comparing Use of Digoxin to Placebo or No Treatment in Patients
While digoxin has been a popular medication in the past, particularly for patients with atrial fibrillation, a recent study looked at whether the medication was indeed beneficial for treatment when compared to placebo or no pharmaceutical therapy at all. Digoxin may be a popular treatment for some patients, but often doctors cannot look at just one condition when treating and have to consider multiple factors and issues.
Q&A With Patrick T. O'Gara From Brigham & Women's Hospital: How 'The Big Simple Trial' Can Help the Future of Clinical Trials
Q&A With Patrick T. O'Gara From Brigham & Women's Hospital: Value Based Care Affects Cardiology Much Like Other Medical Fields
Q&A With Paul Dendale From Hasselt University: Benefits and Risks of Using Telemedicine in Cardiology
As technology improves telemedicine is becoming a more viable option to treat a wide variety of conditions. While the idea of telemedicine can be easily implemented into practice there are still concerns that need to be addressed for the field to progress. These issues can include liability and governance over doctors and where their patients are located.
Q&A With Christi Deaton From Cambridge University: Nursing Changes But Stays True to Origins of Quality Care
In heart failure patients with diabetes and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist called finerenone was no more effective than the currently approved MRA eplerenone in reducing the heart failure biomarker N-terminal pro-B-type natriuretic peptide. But it had other benefits.
Q&A With Jens Nielsen From Aarhus University Hospital: Taking a Deeper Look at Atrial Fibrillation Treatment Options
Q&A With Jens Nielsen From Aarhus University Hospital: MANTRA-PAF Trial Results 5 Years Later for Paroxysmal Atrial Fibrillation Treatment
Q&A With Manolis Kallistratos From Asklepion Voulas General Hospital: Could Taking a Nap Help Hypertensive Patients?
Q&A With Robert Giugliano From Brigham and Women's: Approval of PCSK9 Inhibitors Still Leaves Some Questions
Q&A With Robert Giugliano From Brigham and Women's: PCSK9 Inhibitors Provide Hope for Cardiac Patients
Q&A With Joep Perk From Linnaeus University: Seeing Success in Lifestyle Changes Makes a Difference in Care
Q&A With Maddalena Lettino From Humanitas Research Hospital: Emergency Room Equality and Managing Costs
Q&A With Maddalena Lettino From Humanitas Research Hospital: Diagnosing Myocardial Infarction in the Emergency Room
Q&A With Jagmeet Singh From Harvard Medical School: New Devices and Procedures Mark Future of Atrial Fibrillation Treatment
Q&A With Jagmeet Singh From Harvard Medical School: Looking at New Developments in Atrial Fibrillation Treatment
Syringe Services Program Implemented During HIV Outbreak Led to Reduction of Injection-Related Risk Behaviors